Singapore, July 21 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Amanda Seet Oon Lim
Dr Chia Puey Ling
Published by HT Digital Content Services with permission from Health Daily Digest....